Symbols / CARM $0.03 -0.88% Carisma Therapeutics, Inc.
CARM Chart
About
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.41M |
| Enterprise Value | -596.45K | Income | 8.04M | Sales | 52.63M |
| Book/sh | -0.02 | Cash/sh | 0.07 | Dividend Yield | — |
| Payout | 0.00% | Employees | 46 | IPO | — |
| P/E | 0.18 | Forward P/E | -0.04 | PEG | — |
| P/S | 0.03 | P/B | -1.60 | P/C | — |
| EV/EBITDA | -0.04 | EV/Sales | -0.01 | Quick Ratio | 0.65 |
| Current Ratio | 0.86 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 0.19 | EPS next Y | -0.91 | EPS Growth | — |
| Revenue Growth | 12.37% | Earnings | 2025-08-07 16:00 | ROA | 33.03% |
| ROE | — | ROIC | — | Gross Margin | 48.03% |
| Oper. Margin | 96.83% | Profit Margin | 15.28% | Shs Outstand | 41.85M |
| Shs Float | 30.14M | Short Float | 3.57% | Short Ratio | 0.06 |
| Short Interest | — | 52W High | 1.27 | 52W Low | 0.03 |
| Beta | 3.50 | Avg Volume | 110.50K | Volume | 126.08K |
| Target Price | — | Recom | None | Prev Close | $0.03 |
| Price | $0.03 | Change | -0.88% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.03
Latest analyst target
3. DCF / Fair value
$5.61
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.03
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-08 | main | D. Boral Capital | Buy → Buy | $1 |
| 2025-04-01 | main | D. Boral Capital | Buy → Buy | $1 |
| 2025-01-17 | main | D. Boral Capital | Buy → Buy | $12 |
| 2025-01-13 | main | D. Boral Capital | Buy → Buy | $12 |
| 2024-12-16 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2024-12-12 | main | D. Boral Capital | Buy → Buy | $12 |
| 2024-12-12 | down | Baird | Outperform → Neutral | $1 |
| 2024-12-11 | down | Evercore ISI Group | Outperform → In-Line | $1 |
| 2024-12-10 | down | BTIG | Buy → Neutral | — |
| 2024-12-09 | main | D. Boral Capital | Buy → Buy | $12 |
| 2024-11-25 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-11-18 | main | D. Boral Capital | Buy → Buy | $24 |
| 2024-11-11 | main | D. Boral Capital | Buy → Buy | $24 |
| 2024-11-07 | main | EF Hutton | Buy → Buy | $24 |
| 2024-10-30 | init | EF Hutton | — → Buy | $24 |
| 2024-06-28 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-06-26 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-05-17 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-05-10 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-04-11 | init | BTIG | — → Buy | $6 |
- $CARM stock is down 42% today. Here's what we see in our data. | CARM Stock News - Quiver Quantitative Fri, 10 Oct 2025 07
- Carisma Therapeutics stock plunges after Nasdaq delisting notice - Investing.com Fri, 10 Oct 2025 07
- Can CARISMA Therapeutics Stock Recover If Markets Fall? - Trefis Sun, 21 Dec 2025 08
- Carisma Announces Delisting from Nasdaq and SEC Deregistration - prnewswire.com Fri, 05 Dec 2025 08
- Carisma Therapeutics Faces Nasdaq Delisting and Trading Suspension - TipRanks hu, 09 Oct 2025 07
- Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases - ir.ocugen.com Mon, 23 Jun 2025 07
- Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket - Benzinga ue, 02 Sep 2025 07
- CARM Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 01
- Carisma’s swift exit from Nasdaq signals a dramatic corporate retreat - MSN Fri, 12 Dec 2025 18
- Carisma Therapeutics, OrthoCellix enter definitive merger agreement - Yahoo Finance ue, 24 Jun 2025 07
- BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - - ChartMill Fri, 27 Jun 2025 07
- Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Business And Shares Still Trailing The Industry - simplywall.st Fri, 28 Mar 2025 07
- Carisma Therapeutics (CARM) Stock Forecast and Price Target 2026 - MarketBeat Sat, 11 May 2024 13
- Ocugen merger agreement with Carisma terminated due to funding shortfall - Investing.com hu, 18 Sep 2025 07
- Carisma Therapeutics Provides Corporate Updates - prnewswire.com Mon, 31 Mar 2025 07
Financials
Statement View
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
19.63
+31.59%
|
14.92
+51.71%
|
9.83
|
0.00
|
| Operating Revenue |
|
19.63
+31.59%
|
14.92
+51.71%
|
9.83
|
0.00
|
| Operating Expense |
|
81.81
-21.07%
|
103.65
+57.05%
|
66.00
+61.78%
|
40.79
|
| Research And Development |
|
59.67
-19.50%
|
74.12
+30.92%
|
56.62
+64.65%
|
34.39
|
| Selling General And Administration |
|
22.14
-25.02%
|
29.52
+214.83%
|
9.38
+46.37%
|
6.41
|
| General And Administrative Expense |
|
22.14
-25.02%
|
29.52
+214.83%
|
9.38
+46.37%
|
6.41
|
| Salaries And Wages |
|
9.75
-8.65%
|
10.67
+214.13%
|
3.40
+38.88%
|
2.45
|
| Other Gand A |
|
11.04
-30.85%
|
15.96
+176.67%
|
5.77
+45.67%
|
3.96
|
| Total Expenses |
|
81.81
-21.07%
|
103.65
+57.05%
|
66.00
+61.78%
|
40.79
|
| Operating Income |
|
-62.18
+29.92%
|
-88.73
-57.99%
|
-56.16
-37.67%
|
-40.79
|
| Total Operating Income As Reported |
|
-62.18
+29.92%
|
-88.73
-57.99%
|
-56.16
-37.67%
|
-40.79
|
| EBITDA |
|
-58.83
+31.51%
|
-85.89
-52.87%
|
-56.19
-40.08%
|
-40.11
|
| Normalized EBITDA |
|
-58.83
+31.45%
|
-85.81
-58.12%
|
-54.27
-35.29%
|
-40.11
|
| Reconciled Depreciation |
|
3.35
+18.22%
|
2.84
+49.87%
|
1.89
+177.57%
|
0.68
|
| EBIT |
|
-62.18
+29.92%
|
-88.73
-52.77%
|
-58.08
-42.38%
|
-40.79
|
| Total Unusual Items |
|
—
|
-0.08
+95.62%
|
-1.92
|
—
|
| Total Unusual Items Excluding Goodwill |
|
—
|
-0.08
+95.62%
|
-1.92
|
—
|
| Net Income |
|
-60.48
+30.39%
|
-86.88
-41.90%
|
-61.23
-50.12%
|
-40.78
|
| Pretax Income |
|
-60.48
+30.39%
|
-86.88
-41.90%
|
-61.23
-50.12%
|
-40.78
|
| Net Non Operating Interest Income Expense |
|
1.70
-12.09%
|
1.94
+161.56%
|
-3.15
-31550.00%
|
0.01
|
| Interest Expense Non Operating |
|
—
|
—
|
3.15
|
—
|
| Net Interest Income |
|
1.70
-12.09%
|
1.94
+161.56%
|
-3.15
-31550.00%
|
0.01
|
| Interest Expense |
|
—
|
—
|
3.15
|
—
|
| Interest Income Non Operating |
|
1.70
-12.09%
|
1.94
|
—
|
0.01
|
| Interest Income |
|
1.70
-12.09%
|
1.94
|
—
|
0.01
|
| Other Income Expense |
|
—
|
-0.08
+95.62%
|
-1.92
|
—
|
| Gain On Sale Of Security |
|
—
|
-0.08
+95.62%
|
-1.92
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-60.48
+30.39%
|
-86.88
-41.90%
|
-61.23
-50.12%
|
-40.78
|
| Net Income From Continuing Operation Net Minority Interest |
|
-60.48
+30.39%
|
-86.88
-41.90%
|
-61.23
-50.12%
|
-40.78
|
| Net Income From Continuing And Discontinued Operation |
|
-60.48
+30.39%
|
-86.88
-41.90%
|
-61.23
-50.12%
|
-40.78
|
| Net Income Continuous Operations |
|
-60.48
+30.39%
|
-86.88
-41.90%
|
-61.23
-50.12%
|
-40.78
|
| Normalized Income |
|
-60.48
+30.32%
|
-86.80
-46.35%
|
-59.31
-45.42%
|
-40.78
|
| Net Income Common Stockholders |
|
-60.48
+30.39%
|
-86.88
-41.90%
|
-61.23
-50.12%
|
-40.78
|
| Diluted EPS |
|
-1.46
+43.63%
|
-2.59
-70.29%
|
-1.52
-50.12%
|
-1.01
|
| Basic EPS |
|
-1.46
+43.63%
|
-2.59
-70.29%
|
-1.52
-50.12%
|
-1.01
|
| Basic Average Shares |
|
41.46
+23.66%
|
33.52
-16.72%
|
40.25
+0.00%
|
40.25
|
| Diluted Average Shares |
|
41.46
+23.66%
|
33.52
-16.72%
|
40.25
+0.00%
|
40.25
|
| Diluted NI Availto Com Stockholders |
|
-60.48
+30.39%
|
-86.88
-41.90%
|
-61.23
-50.12%
|
-40.78
|
| Insurance And Claims |
|
1.35
-53.25%
|
2.89
+1269.67%
|
0.21
|
—
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
30.46
-65.99%
|
89.55
+24.12%
|
72.15
+103.54%
|
35.45
|
| Current Assets |
|
23.82
-70.39%
|
80.47
+47.40%
|
54.59
+83.28%
|
29.79
|
| Cash Cash Equivalents And Short Term Investments |
|
17.91
-76.92%
|
77.61
+49.25%
|
52.00
+82.12%
|
28.55
|
| Cash And Cash Equivalents |
|
17.91
-76.92%
|
77.61
+220.76%
|
24.19
-15.26%
|
28.55
|
| Other Short Term Investments |
|
—
|
0.00
-100.00%
|
27.80
|
—
|
| Prepaid Assets |
|
—
|
—
|
—
|
1.24
|
| Other Current Assets |
|
5.92
+106.42%
|
2.87
+10.40%
|
2.60
+110.20%
|
1.24
|
| Total Non Current Assets |
|
6.63
-26.97%
|
9.08
-48.28%
|
17.56
+210.10%
|
5.66
|
| Net PPE |
|
6.42
-28.11%
|
8.94
-33.55%
|
13.45
+137.51%
|
5.66
|
| Gross PPE |
|
14.31
-5.14%
|
15.09
-10.00%
|
16.76
+136.65%
|
7.08
|
| Accumulated Depreciation |
|
-7.89
-28.22%
|
-6.15
-85.61%
|
-3.31
-133.22%
|
-1.42
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.78
-33.76%
|
1.17
-11.96%
|
1.33
+176.30%
|
0.48
|
| Construction In Progress |
|
0.00
-100.00%
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
| Other Properties |
|
13.20
-2.71%
|
13.56
-10.06%
|
15.08
+140.43%
|
6.27
|
| Leases |
|
0.34
+0.00%
|
0.34
+0.00%
|
0.34
+7.26%
|
0.32
|
| Non Current Deferred Assets |
|
0.21
+42.47%
|
0.15
-96.45%
|
4.11
|
—
|
| Total Liabilities Net Minority Interest |
|
58.37
-7.39%
|
63.02
-70.66%
|
214.82
+2179.29%
|
9.43
|
| Current Liabilities |
|
16.05
+0.92%
|
15.91
-19.13%
|
19.67
+155.75%
|
7.69
|
| Payables And Accrued Expenses |
|
4.65
-45.26%
|
8.49
-8.46%
|
9.28
+36.61%
|
6.79
|
| Payables |
|
2.08
-47.09%
|
3.93
+127.60%
|
1.73
-25.58%
|
2.32
|
| Accounts Payable |
|
2.08
-47.09%
|
3.93
+127.60%
|
1.73
-25.58%
|
2.32
|
| Current Accrued Expenses |
|
2.57
-43.69%
|
4.56
-39.59%
|
7.55
+68.91%
|
4.47
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
4.88
+57.39%
|
3.10
+10.36%
|
2.81
|
—
|
| Current Debt And Capital Lease Obligation |
|
1.74
-10.23%
|
1.94
-57.93%
|
4.60
+412.14%
|
0.90
|
| Current Capital Lease Obligation |
|
1.74
-10.23%
|
1.94
-57.93%
|
4.60
+412.14%
|
0.90
|
| Current Deferred Liabilities |
|
3.73
+163.91%
|
1.41
-42.54%
|
2.46
|
—
|
| Current Deferred Revenue |
|
3.73
+163.91%
|
1.41
-42.54%
|
2.46
|
—
|
| Other Current Liabilities |
|
1.06
+9.84%
|
0.96
+84.51%
|
0.52
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
42.31
-10.19%
|
47.11
-75.86%
|
195.15
+11154.50%
|
1.73
|
| Long Term Debt And Capital Lease Obligation |
|
0.74
-37.37%
|
1.19
-96.66%
|
35.56
+1951.04%
|
1.73
|
| Long Term Debt |
|
—
|
—
|
33.72
|
—
|
| Long Term Capital Lease Obligation |
|
0.74
-37.37%
|
1.19
-35.71%
|
1.85
+6.57%
|
1.73
|
| Non Current Deferred Liabilities |
|
41.25
-8.33%
|
45.00
+0.00%
|
45.00
|
—
|
| Non Current Deferred Revenue |
|
41.25
-8.33%
|
45.00
+0.00%
|
45.00
|
—
|
| Other Non Current Liabilities |
|
0.32
-65.66%
|
0.93
-11.05%
|
1.04
|
—
|
| Preferred Securities Outside Stock Equity |
|
—
|
0.00
-100.00%
|
107.81
|
—
|
| Stockholders Equity |
|
-27.91
-205.19%
|
26.53
+116.89%
|
-157.06
-1450.63%
|
11.63
|
| Common Stock Equity |
|
-27.91
-205.19%
|
26.53
+116.89%
|
-157.06
-63.30%
|
-96.18
|
| Capital Stock |
|
0.04
+2.50%
|
0.04
+1900.00%
|
0.00
-100.00%
|
107.81
|
| Common Stock |
|
0.04
+2.50%
|
0.04
+1900.00%
|
0.00
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
-100.00%
|
107.81
|
| Share Issued |
|
41.75
+2.81%
|
40.61
+0.88%
|
40.25
+0.00%
|
40.25
|
| Ordinary Shares Number |
|
41.75
+2.81%
|
40.61
+0.88%
|
40.25
+0.00%
|
40.25
|
| Additional Paid In Capital |
|
277.63
+2.22%
|
271.59
+22589.56%
|
1.20
+46.33%
|
0.82
|
| Retained Earnings |
|
-305.58
-24.67%
|
-245.10
-54.91%
|
-158.22
-63.12%
|
-97.00
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
0.00
+100.00%
|
-0.04
|
—
|
| Minority Interest |
|
—
|
0.00
-100.00%
|
14.39
+0.00%
|
14.39
|
| Other Equity Adjustments |
|
—
|
—
|
-0.04
|
—
|
| Total Equity Gross Minority Interest |
|
-27.91
-205.19%
|
26.53
+118.60%
|
-142.67
-648.22%
|
26.02
|
| Total Capitalization |
|
-27.91
-205.19%
|
26.53
+121.51%
|
-123.35
-1160.69%
|
11.63
|
| Working Capital |
|
7.77
-87.97%
|
64.56
+84.88%
|
34.92
+58.05%
|
22.09
|
| Invested Capital |
|
-27.91
-205.19%
|
26.53
+121.51%
|
-123.35
-28.25%
|
-96.18
|
| Total Debt |
|
2.48
-20.56%
|
3.12
-92.22%
|
40.16
+1425.99%
|
2.63
|
| Net Debt |
|
—
|
—
|
9.52
|
—
|
| Capital Lease Obligations |
|
2.48
-20.56%
|
3.12
-51.56%
|
6.45
+144.95%
|
2.63
|
| Net Tangible Assets |
|
-27.91
-205.19%
|
26.53
+116.89%
|
-157.06
-1450.63%
|
11.63
|
| Tangible Book Value |
|
-27.91
-205.19%
|
26.53
+116.89%
|
-157.06
-63.30%
|
-96.18
|
| Derivative Product Liabilities |
|
—
|
0.00
-100.00%
|
5.74
|
—
|
| Interest Payable |
|
—
|
0.00
-100.00%
|
1.13
|
—
|
| Preferred Stock Equity |
|
—
|
—
|
—
|
107.81
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-59.92
+26.19%
|
-81.18
-1486.73%
|
-5.12
+86.29%
|
-37.33
|
| Cash Flow From Continuing Operating Activities |
|
-59.92
+26.19%
|
-81.18
-1486.73%
|
-5.12
+86.29%
|
-37.33
|
| Net Income From Continuing Operations |
|
-60.48
+30.39%
|
-86.88
-41.90%
|
-61.23
-50.12%
|
-40.78
|
| Depreciation Amortization Depletion |
|
3.35
+18.22%
|
2.84
+49.87%
|
1.89
+177.57%
|
0.68
|
| Depreciation And Amortization |
|
3.35
+18.22%
|
2.84
+49.87%
|
1.89
+177.57%
|
0.68
|
| Other Non Cash Items |
|
5.18
-24.38%
|
6.85
+0.34%
|
6.83
+718.59%
|
0.83
|
| Stock Based Compensation |
|
3.65
+57.56%
|
2.32
+742.18%
|
0.28
-42.59%
|
0.48
|
| Asset Impairment Charge |
|
0.36
|
0.00
|
—
|
—
|
| Operating Gains Losses |
|
-0.03
+78.85%
|
-0.16
-108.13%
|
1.92
|
—
|
| Gain Loss On Investment Securities |
|
—
|
-0.32
-116.41%
|
1.92
|
—
|
| Gain Loss On Sale Of PPE |
|
-0.03
-120.75%
|
0.16
|
0.00
|
—
|
| Change In Working Capital |
|
-11.95
-119.87%
|
-5.44
-112.03%
|
45.20
+2993.50%
|
1.46
|
| Change In Prepaid Assets |
|
-3.12
-398.28%
|
1.05
+176.86%
|
-1.36
-637.94%
|
0.25
|
| Change In Payables And Accrued Expense |
|
-2.06
-191.67%
|
-0.71
-118.84%
|
3.76
+85.90%
|
2.02
|
| Change In Accrued Expense |
|
-0.21
+92.65%
|
-2.90
-168.53%
|
4.23
+41.24%
|
3.00
|
| Change In Payable |
|
-1.85
-184.53%
|
2.19
+563.21%
|
-0.47
+51.44%
|
-0.97
|
| Change In Account Payable |
|
-1.85
-184.53%
|
2.19
+563.21%
|
-0.47
+51.44%
|
-0.97
|
| Change In Other Working Capital |
|
-1.43
-37.09%
|
-1.05
-102.20%
|
47.46
|
—
|
| Change In Other Current Liabilities |
|
-5.33
-12.80%
|
-4.73
-1.48%
|
-4.66
-473.06%
|
-0.81
|
| Investing Cash Flow |
|
-0.12
-100.17%
|
72.41
+322.38%
|
-32.56
-1640.25%
|
-1.87
|
| Cash Flow From Continuing Investing Activities |
|
-0.12
-100.17%
|
72.41
+322.38%
|
-32.56
-1640.25%
|
-1.87
|
| Net PPE Purchase And Sale |
|
-0.12
+89.13%
|
-1.13
+75.71%
|
-4.66
-149.06%
|
-1.87
|
| Purchase Of PPE |
|
-0.12
+89.13%
|
-1.13
+75.71%
|
-4.66
-149.06%
|
-1.87
|
| Capital Expenditure |
|
-0.12
+89.13%
|
-1.13
+75.71%
|
-4.66
-149.06%
|
-1.87
|
| Net Investment Purchase And Sale |
|
0.00
-100.00%
|
73.54
+363.58%
|
-27.90
|
—
|
| Purchase Of Investment |
|
0.00
+100.00%
|
-34.46
+62.09%
|
-90.90
|
—
|
| Sale Of Investment |
|
0.00
-100.00%
|
108.00
+71.43%
|
63.00
|
—
|
| Financing Cash Flow |
|
0.34
-99.45%
|
62.18
+86.62%
|
33.32
+108.74%
|
15.96
|
| Cash Flow From Continuing Financing Activities |
|
0.34
-99.45%
|
62.18
+86.62%
|
33.32
+108.74%
|
15.96
|
| Net Issuance Payments Of Debt |
|
-1.43
-9.84%
|
-1.30
-103.81%
|
34.13
|
—
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
35.00
|
—
|
| Repayment Of Debt |
|
-1.43
-9.84%
|
-1.30
-50.40%
|
-0.86
|
—
|
| Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
35.00
|
—
|
| Long Term Debt Payments |
|
-1.43
-9.84%
|
-1.30
-50.40%
|
-0.86
|
—
|
| Net Long Term Debt Issuance |
|
-1.43
-9.84%
|
-1.30
-103.81%
|
34.13
|
—
|
| Net Common Stock Issuance |
|
2.39
-92.34%
|
31.24
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
0.00
-97.86%
|
0.19
+76.42%
|
0.11
|
0.00
|
| Net Other Financing Charges |
|
-0.62
-101.94%
|
32.06
+3576.90%
|
-0.92
-151.91%
|
-0.37
|
| Changes In Cash |
|
-59.70
-211.77%
|
53.41
+1325.87%
|
-4.36
+81.25%
|
-23.24
|
| Beginning Cash Position |
|
77.61
+220.76%
|
24.19
-15.26%
|
28.55
-44.87%
|
51.79
|
| End Cash Position |
|
17.91
-76.92%
|
77.61
+220.76%
|
24.19
-15.26%
|
28.55
|
| Free Cash Flow |
|
-60.04
+27.06%
|
-82.31
-741.95%
|
-9.78
+75.06%
|
-39.20
|
| Interest Paid Supplemental Data |
|
0.19
-45.45%
|
0.35
+259.18%
|
0.10
|
—
|
| Amortization Of Securities |
|
0.00
+100.00%
|
-0.71
|
0.00
|
—
|
| Common Stock Issuance |
|
2.39
-92.34%
|
31.24
|
0.00
|
—
|
| Issuance Of Capital Stock |
|
2.39
-92.34%
|
31.24
|
0.00
-100.00%
|
16.33
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
16.33
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
16.33
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2025-12-05 View
- 10-Q2025-11-12 View
- 8-K2025-10-15 View
- 8-K2025-10-09 View
- 42025-10-08 View
- 42025-10-03 View
- 8-K2025-09-18 View
- 8-K2025-08-29 View
- 8-K2025-08-08 View
- 10-Q2025-08-07 View
- 8-K2025-07-15 View
- 8-K2025-06-23 View
- 8-K2025-06-12 View
- 10-Q2025-05-13 View
- 8-K2025-04-16 View
- 10-K2025-03-31 View
- 42025-01-30 View
- 42025-01-30 View
- 8-K2025-01-13 View
- 8-K2025-01-10 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|